Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Alzheimer's Disease Clinical Trial

— PROGRESS-AD  

Official title:

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06079190
• Other study ID #: 219867
• Secondary ID: 2023-505083-11-0
• Status: Recruiting
• Phase: Phase 2
• Start date: October 20, 2023
• Est. completion date: May 16, 2029

Study information

• Verified date: February 2024
• Source: GlaxoSmithKline
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 282
• Est. completion date: May 16, 2029
• Est. primary completion date: December 2, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

Participant must be in the Alzheimer's continuum as defined by the 2018 National Institute on Aging and Alzheimer's Association (NIAAA) Research Framework corresponding to the clinical categories of MCI due to AD and mild AD dementia. Participant must have evidence of amyloid positivity either by positive positron emission tomography (PET) result (Amyloid PET scans must be read by a central imaging lab) or cerebrospinal fluid (CSF) amyloid beta (Aß) test result indicative of amyloid positivity

• Participants must also meet the following criteria for clinical severity:

1. MMSE score of between 21 and 29 points

2. CDR-global score (GS) of 0.5 to 1.0.

3. CDR Memory Box score greater than or equal to (=) 0.5.

4. Participants with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale-IV Logical Memory II (WMS-IV LMII)

• If the participant is receiving symptomatic AD medications such as an Acetylcholinesterase inhibitor (AChEI) or memantine, the dosing regimen must have been stable for at least 12 weeks prior to screening and is not expected to change during study participation.
• If the participant is receiving other medications for AD related symptoms or associated conditions, the dosing regimen must have been stable for at least 4 weeks prior to screening and not expected to change during study participation. Symptoms must be considered adequately and stably controlled by the investigator, without marked changes in medication anticipated for the duration of the study.
• Body weight = 45 kilogram (kg) to less than or equal to (=)120 kg with body mass index (BMI) between 17 and 34.9 kilogram per meter square (kg/m^2), inclusive.
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of child-bearing potential follows contraception requirements outlined in the protocol
• A male participant is eligible to participate if he follows contraception requirements outlined in the protocol
• Willing and able to give informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
• Availability of an adult person who has frequent and sufficient contact with the participant is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the ICF of the study partner. Exclusion Criteria: Participant has evidence of any neurological condition other than AD that may contribute to cognitive impairment.
• History or presence of vascular disease that has the potential to affect cognitive function.
• History or presence of stroke within the past 1 year or recent transient ischemic attack within 180 days before screening.
• History of severe, clinically significant central nervous system (CNS) trauma.
• History or presence of intracranial tumor.
• Presence of ongoing infection(s) that may affect brain function, or history of infections that resulted in neurologic sequelae.
• History of primary psychiatric diagnosis that the investigator considers may interfere with study assessments. Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, suicidal behaviour or has been assessed to be at risk of suicide, in the opinion of the investigator within 6 months before screening, at screening, or at the Baseline visit, or has been hospitalized or treated for suicidal behaviour in the past 2 years.
• Participant has history of alcohol and/or moderate to severe substance use disorder within the past 2 years
• Magnetic resonance imaging (MRI) evidence based on central read of:

1. >3 lacunar infarcts.

2. Stroke involving a major vascular territory, severe small vessel, or white matter disease.

3. Any territorial infarct >1 cubic centimetre (cm^3).

4. White matter hyperintense lesions on the FLAIR sequence that correspond to an overall Fazekas score of 3

5. >4 microhaemorrhages.

6. Any areas of superficial (leptomeningeal) hemosiderosis.

7. A single macro-hemorrhage greater than 10 millimetres (mm) at greatest diameter.

8. Vasogenic edema.

9. Cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions.

10. Space occupying lesions or brain tumors.

11. Significant cerebral vascular pathology

• History suggestive of exposure to, or past tuberculosis (TB) infection should undergo screening for TB disease.
• Chronic active immune disorder requiring systemic immunosuppressive therapy within 6 months prior to Screening.
• Screening serum vitamin B12 concentration < Lower limit of normal (LLN) or in the low normal range
• Folate <LLN or Thyroid-stimulating hormone (TSH) > Upper limit of normal (ULN)
• Hemoglobin A1c >8 percentage (%) or poorly controlled diabetes during the last 12 weeks
• History of cancer
• Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
• Planned surgery during the study which requires general, spinal, or epidural anesthesia that would take place during the study.
• Key exclusionary medications include:
• Antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood stabilizers, or stimulants that are used on a chronic basis, are exclusionary if not consistent with the following rule: treatment has to have been at a stable dose for at least 4 weeks before screening and should remain stable during the study
• Any biologic drugs with systemic exposure, whether investigational or approved, used within 6 months before screening Any disease modification drug for AD, such as aducanumab and lecanemab, whether investigational or approved, used within 6 months before screening.
• Anticoagulation medications within 90 days of screening and during the study
• Systemic immunosuppressive therapy within 90 days before screening and during the study.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• GSK4527226
GSK4527226 will be administered.

Other:
• Placebo
Placebo will be administered.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Buenos Aires
Argentina	GSK Investigational Site	Capital Federal	Buenos Aires
Argentina	GSK Investigational Site	Ciudad Autonoma de Buenos Aires	Buenos Aires
Australia	GSK Investigational Site	Camperdown	New South Wales
Australia	GSK Investigational Site	Darlinghurst	New South Wales
Australia	GSK Investigational Site	Ivanhoe	Victoria
Australia	GSK Investigational Site	Kogarah	New South Wales
Australia	GSK Investigational Site	Macquarie Park	New South Wales
Australia	GSK Investigational Site	Melbourne	Victoria
Australia	GSK Investigational Site	Nedlands	Western Australia
Australia	GSK Investigational Site	Southport	Queensland
Canada	GSK Investigational Site	Greenfield-Park	Quebec
Canada	GSK Investigational Site	Ottawa	Ontario
Canada	GSK Investigational Site	Peterborough	Ontario
Canada	GSK Investigational Site	Sherbrooke	Quebec
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Verdun	Quebec
Finland	GSK Investigational Site	Helsinki
Finland	GSK Investigational Site	Kuopio
Finland	GSK Investigational Site	Oulu
Finland	GSK Investigational Site	Turku
France	GSK Investigational Site	Bron
France	GSK Investigational Site	Lille Cedex
France	GSK Investigational Site	Nice
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Saint-Herblain
France	GSK Investigational Site	Strasbourg
France	GSK Investigational Site	Toulouse
France	GSK Investigational Site	Villeurbanne
Germany	GSK Investigational Site	Erbach	Hessen
Germany	GSK Investigational Site	Koeln	Nordrhein-Westfalen
Germany	GSK Investigational Site	Muenchen	Bayern
Germany	GSK Investigational Site	Muenster	Nordrhein-Westfalen
Italy	GSK Investigational Site	Baggiovara	Modena
Italy	GSK Investigational Site	Brescia
Italy	GSK Investigational Site	Cefalù	Palermo
Italy	GSK Investigational Site	Genova	Liguria
Italy	GSK Investigational Site	Milano
Italy	GSK Investigational Site	Milano
Italy	GSK Investigational Site	Mondino	Pavia
Italy	GSK Investigational Site	Monza
Italy	GSK Investigational Site	Palermo
Italy	GSK Investigational Site	Perugia
Italy	GSK Investigational Site	Roma	Lazio
Korea, Republic of	GSK Investigational Site	Jung Gu
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
Netherlands	GSK Investigational Site	's-Hertogenbosch
Netherlands	GSK Investigational Site	Amsterdam
Netherlands	GSK Investigational Site	Zwolle
Norway	GSK Investigational Site	Bergen
Norway	GSK Investigational Site	Drammen
Norway	GSK Investigational Site	Oslo
Norway	GSK Investigational Site	Stavanger
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Getxo
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Pamplona
Spain	GSK Investigational Site	Pozuelo De Alarcón	Madrid
Spain	GSK Investigational Site	Salamanca
Spain	GSK Investigational Site	San Sebastian	País Vasco
Spain	GSK Investigational Site	Terrassa (Barcelona)
Spain	GSK Investigational Site	Valencia
Sweden	GSK Investigational Site	Jönköping
Sweden	GSK Investigational Site	Malmö
Sweden	GSK Investigational Site	Mölndal
Sweden	GSK Investigational Site	Stockholm
Taiwan	GSK Investigational Site	Kaohsiung
Taiwan	GSK Investigational Site	Tainan
Taiwan	GSK Investigational Site	Taoyuan
Turkey	GSK Investigational Site	Ankara
Turkey	GSK Investigational Site	Capa/Istanbul
United Kingdom	GSK Investigational Site	Birmingham	England
United Kingdom	GSK Investigational Site	Bristol
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	Motherwell
United States	GSK Investigational Site	Charleston	South Carolina
United States	GSK Investigational Site	Chesterfield	Missouri
United States	GSK Investigational Site	Decatur	Georgia
United States	GSK Investigational Site	DeLand	Florida
United States	GSK Investigational Site	Elk Grove Village	Illinois
United States	GSK Investigational Site	Fairfax	Virginia
United States	GSK Investigational Site	Houston	Texas
United States	GSK Investigational Site	Maitland	Florida
United States	GSK Investigational Site	Matthews	North Carolina
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	North Canton	Ohio
United States	GSK Investigational Site	Oklahoma City	Oklahoma
United States	GSK Investigational Site	Orlando	Florida
United States	GSK Investigational Site	Portland	Oregon
United States	GSK Investigational Site	San Diego	California
United States	GSK Investigational Site	Staten Island	New York
United States	GSK Investigational Site	Stuart	Florida
United States	GSK Investigational Site	The Villages	Florida
United States	GSK Investigational Site	Toms River	New Jersey
United States	GSK Investigational Site	Wichita	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	Alector Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  Finland,  France,  Germany,  Italy,  Korea, Republic of,  Netherlands,  Norway,  Spain,  Sweden,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The CDR-SB score is a quantitative general index that provides more precision in participants with mild dementia. The CDR scale is a clinician-rated dementia staging system tracks the progression of. cognitive impairment in 6 categories (memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5- point scale in which None=0, Questionable=0.5, Mild=1, Moderate=2, and Severe=3. The CDR-SB is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.	Baseline, Week 52, 64 and 76
Secondary	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The iADRS is a composite score that measures both cognition and function. The iADRS comprises scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimers Disease Cooperative Study-instrumental Activities of Daily Living (ADCS-iADL). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog14 (14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. Higher scores indicate greater impairment) and the ADCS-iADL (score range from 0-49 with higher scores reflecting better performance and lower scores indicating greater functional impairment).	Baseline, Weeks 52, 64 and 76
Secondary	Change from Baseline in ADAS-Cog14 Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The AD Assessment Scale-Cognitive subscale (ADAS-Cog14) is a 14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. Score ranges from 0 to 90 and higher scores indicate greater impairment.	Baseline, Weeks 52, 64 and 76
Secondary	Change from Baseline in ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The AD Cooperative Study - Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-ADL-MCI). The ADCS-ADL for MCI is a 23-item scale that measures the competence of participants in basic and instrumental activities of daily living. Total scores on the ADCS-ADL-MCI range from 0 to 53 where lower scores indicates greater functional impairment.	Baseline, Weeks 52, 64 and 76
Secondary	Change from Baseline in ADCS-iADL component of ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The ADCS-iADL is a subscale which measures instrumental activities of daily living. The ADCS-iADL is derived from the ADCS-ADL-MCI. It has a total score ranging from 0 to 49 with lower scores indicating greater functional impairment.	Baseline, Weeks 52, 64 and 76
Secondary	Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) for Dose 1 vs Placebo Across Weeks 52, 64 and 76	The ADCOMS is a composite score comprising scores from various items of the Mini-Mental Status Examination (MMSE), ADAS-Cog14, and CDR domains. The MMSE is a brief test used to screen for cognitive impairment. It is routinely used for estimating the severity of cognitive impairment and tracking cognitive changes in an individual over time. It assesses orientation (time and place), registration, attention and calculation, recent memory, language (naming, comprehension, and repetition), and constructional praxis (copying a figure). For ADCOMS a higher score is indicative of greater impairment.	Baseline, Weeks 52, 64 and 76